Adaptimmune Therapeutics PLC
ADAPY- Exchange
- OTC
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001621227
No open-market purchases or sales by Adaptimmune Therapeutics PLC insiders were filed in the last 90 days; no institution reported holding it in 13F filings for Q2 2026; no superinvestor holds it.
Q1 2025 vs. Q4 2024
How the institutions holding Adaptimmune Therapeutics PLC changed between Q4 2024 and Q1 2025.
All holders in Q1 2025All holders in Q4 2024
| Measure | Q4 2024 | Of which not filed for Q1 2025 | Q1 2025 | Change |
|---|---|---|---|---|
| Holders | 80 | 2 | 67 | −11 |
| Shares | 124.4M | 33.1K | 116.1M | −8.32M (−6.7%) |
| Value | $67.0M | $17.8K | $22.9M | −$44.2M (−65.9%) |
2 institutions that held it in Q4 2024 haven't filed for Q1 2025 yet. Not filing isn't selling, so the changes leave them out.
New holders (8)
Institutions that held Adaptimmune Therapeutics PLC at the end of Q1 2025 but not at the end of Q4 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| State of Tennessee, Treasury Department | 73,376 | $14.5K | 0.00% |
| SEI Investments Co | 54,824 | $10.8K | 0.00% |
| State of New Jersey Common Pension Fund D | 54,718 | $10.8K | 0.00% |
| Ausdal Financial Partners, Inc. | 12,476 | $2.46K | 0.00% |
| Qube Research & Technologies Ltd | 10,113 | $1.99K | 0.00% |
| IFG Advisory, LLC | 10,000 | $1.97K | 0.00% |
| Farther Finance Advisors, LLC | 20 | $5 | 0.00% |
| SBI Securities Co., Ltd. | 10 | $2 | 0.00% |
Sold out (19)
Institutions that held Adaptimmune Therapeutics PLC at the end of Q4 2024 and filed for Q1 2025 without it.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Baillie Gifford & Co | 11,819,095 | $6.37M |
| PFM Health Sciences, LP | 4,871,969 | $2.62M |
| Redmile Group, LLC | 715,607 | $385.5K |
| Marshall Wace, LLP | 529,123 | $285.7K |
| Jane Street Group, LLC | 326,937 | $176.1K |
| LPL Financial LLC | 183,479 | $98.8K |
| Citadel Advisors LLC | 175,052 | $94.3K |
| Virtu Financial LLC | 122,696 | $66.0K |
| HRT Financial LP | 83,199 | $44.0K |
| Palisades Investment Partners, LLC | 47,114 | $25.4K |
| Vontobel Holding Ltd. | 43,000 | $23.2K |
| Oppenheimer & Co Inc | 32,043 | $17.3K |
| Hunter Associates Investment Management LLC | 22,000 | $12.0K |
| Kingswood Wealth Advisors, LLC | 18,690 | $10.1K |
| PKS Advisory Services, LLC | 17,000 | $9.16K |
| Squarepoint Ops LLC | 16,563 | $8.92K |
| Baader Bank INC | 18,095 | $8.73K |
| R Squared Ltd | 8,770 | $4.72K |
| IFP Advisors, Inc | 3,023 | $1.63K |
Not filed for Q1 2025 yet (2)
Institutions that held Adaptimmune Therapeutics PLC at the end of Q4 2024 and haven't filed a 13F for Q1 2025. Not filing isn't selling, so they aren't counted as sold out.
| Institution | Shares, Q4 2024 | Value, Q4 2024 |
|---|---|---|
| Legacy Capital Wealth Management, LLC | 27,080 | $14.6K |
| Global Retirement Partners, LLC | 6,000 | $3.23K |